DICE Therapeutics
Ram Devarapalli has over 19 years of experience in the pharmaceutical and biotechnology industry. Ram is currently serving as the Head of Clinical Informatics & Analytics at DICE Therapeutics since May 2022. Prior to that, they worked at Taysha Gene Therapies as the Associate Director, Central Data Monitoring, Reporting & Analytics from August 2021 to May 2022.
From October 2016 to August 2021, Ram held the position of Associate Director, Data technologies & programming at Covance. Before that, they worked as a Sr Manager, Clinical Programming at Chiltern from July 2014 to October 2016.
Ram has also had valuable experience at Theorem Clinical Research, serving as the Manager, Clinical Programming from August 2012 to July 2014, and as a Senior Clinical Programmer from September 2007 to July 2012. Prior to that, they worked as a Programmer Analyst at Clinforce GSK Outsourcing Group from August 2005 to September 2007, and as an OC Programmer at Pfizer from November 2003 to November 2004.
Ram Devarapalli earned a Master of Science degree in Software Engineering from the University of St. Thomas from 2000 to 2002.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.